Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue SUPPL. 1, 2005, Pages 83-91

  Castro Faria Neto, Hugo C ^a   Stafforini, Diana M ^b   Prescott, Stephen M ^b   Zimmerman, Guy A ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Acethylhydrolase; Inflammatory disease; Platelet activating factor; Sepsis

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 1 O ALKYLGLYCERO 3 PHOSPHORYLCHOLINE; ACETIC ACID DERIVATIVE; CALCIUM; CELL ENZYME; GLYCEROL; LIPID; PHOSPHOLIPASE A2; PHOSPHOLIPID; RECOMBINANT ENZYME; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BIOCHEMISTRY; BIODEGRADATION; CARDIOVASCULAR DISEASE; CATALYSIS; CLINICAL TRIAL; CONFERENCE PAPER; DEACETYLATION; DISEASE ASSOCIATION; DISEASE MODEL; ENDOTOXEMIA; ENZYME ANALYSIS; ENZYME REPLACEMENT; ENZYME SUBSTRATE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC POLYMORPHISM; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LIPID OXIDATION; MAMMAL; MEDIATOR; METABOLITE; NONHUMAN; PATHOPHYSIOLOGY; PLASMA; REGULATORY MECHANISM; SEPSIS; SIGNAL TRANSDUCTION; THROMBOSIS;

MAMMALIA;

EID: 18844421079     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762005000900014     Document Type: Conference Paper

References (88)

1. Ambrosio G, Oriente A, Napoli C, Palumbo G, Chiariello P, Marone G et al. 1994. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest 93: 2408-2416.
2. Angus DC, Wax RS 2001. Epidemiology of sepsis: an update. Crit Care Med 29: S109-116.
3. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M et al. 1999. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 261: 511-514.
4. Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C 2001. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thromb Res 101: 231-234.
5. Bazan NG, Squinto SP, Braquet P, Panetta T, Marcheselli VL 1991. Platelet-activating factor and polyunsaturated fatty acids in cerebral ischemia or convulsions: intracellular PAF-binding sites and activation of a fos/jun/AP-1 transcriptional signaling system. Lipids 26: 1236-1242.
6. Blank ML, Lee T, Fitzgerald V, Snyder F 1981. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem 256: 175-178.
7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
8. Bozza PT, Castro-Faria-Neto HC, Silva AR, Larangeira AP, Silva PM, Martins MA et al. 1994. Lipopolysaccharide-induced pleural neutrophil accumulation depends on marrow neutrophils and platelet-activating factor. Eur J Pharmacol 270: 143-149.
9. Bussolino F, Porcellini MG, Varese L, Bosia A 1987. Intravascular release of platelet activating factor in children with sepsis. Thromb Res 48: 619-620.
10. Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM 1998. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem 273: 4012-4020.
11. Chang SW, Feddersen CO, Henson PM, Voelkel NF 1987. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 79: 1498-1509.
12. Chang SW, Fernyak S, Voelkel NF 1990. Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury. Am J Physiol 258: H153-158.
13. Chen CH 2004. Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr Opin Lipidol 15: 337-341.
14. Cordeiro RS, Martins MA, Silva PM, Faria Neto HC, Castanheira JR, Vargaftig BB 1986. Desensitization to PAF-induced rat paw oedema by repeated intraplantar injections. Life Sci 39: 1871-1878.
15. Dhainaut JF, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P et al. 1998. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 26: 1963-1971.
16. e Silva PM, Martins MA, Faria Neto HC, Cordeiro RS, Vargaftig BB 1991. Generation of an eosinophilotactic activity in the pleural cavity of platelet-activating factor-injected rats. J Pharmacol Exp Ther 257: 1039-1044.
17. Eisaf M, Tselepis AD 2003. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol 66: 2069-2073.
18. Elstad MR, Stafforini DM, McIntyre TM, Prescott SM, Zimmerman GA 1989. Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. J Biol Chem 264: 8467-8470.
19. Fukuda Y, Kawashima H, Saito K, Inomata N, Matsui M, Nakanishi T 2000. Effect of human plasma-type platelet-activating factor acetylhydrolase in two anaphylactic shock models. Eur J Pharmacol 390: 203-207.
20. Glauser MP 2000. Pathophysiologic basis of sepsis: considerations for future strategies of intervention. Crit Care Med 28: S4-8.
21. Graham RM, Stephens CJ, Silvester W, Leong LL, Sturm MJ, Taylor RR 1994. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 22: 204-212.
22. Hattori K, Hattori M, Adachi H, Tsujimoto M, Arai H, Inoue K 1995. Purification and characterization of platelet-activating factor acetylhydrolase II from bovine liver cytosol. J Biol Chem 270: 22308-22313.
23. Hattori M, Adachi H, Tsujimoto M, Arai H, Inoue K 1994. Miller-Dicker lissencephaly gene encodes a subunit of brain platelet-activating factor acetylhydrolase [corrected]. Nature 370: 216-218.
24. Henderson Jr WR, Lu J, Poole KM, Dietsch GN, Chi EY 2000. Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model. J Immunol 164:3360-3367.
25. Henig NR, Aitken ML, Liu MC, Yu AS, Henderson Jr WR 2000. Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am J Respir Crit Care Med 162: 523-527.
26. Heuer HO 1991. Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists. Lipids 26: 1369-1373.
27. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K 1997. A mutation in plasma platelet-activating factor acetylhydrolase (Val279->Phe) is a genetic risk factor for stroke. Stroke 28: 2417-2420.
28. Honda Z, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y et al. 1991. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature 349: 342-346.
29. Howard KM, Olson MS 2000. The expression and localization of plasma platelet-activating factor acetylhydrolase in endotoxemic rats. J Biol Chem 275: 19891-19896.
30. Howard KM, Miller JE, Miwa M, Olson MS 1997. Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver. J Biol Chem 272: 27543-27548.
31. Ichihara S, Yamada Y, Yokota M 1998. Association of a G994 ->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese. Circulation 98: 1881-1885.
32. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA 1995. Platelet-activating factor: a mediator for clinicians. J Intern Med 238: 5-20.
33. Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S et al. 1998. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med 187: 1779-1788.
34. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M 2003. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 42: 93-114.
35. Lopez Diez F, Nieto ML, Fernandez-Gallardo S, Gijon MA, Sanchez Crespo M 1989. Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 83: 1733-1740.
36. Lorant DE, Patel KD, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA 1991. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biol 115: 223-234.
37. Loucks EB, Symersky P, Qayumi AK 1997. Platelet-activating factor antagonism: a new concept in the management of regional myocardial ischemia-reperfusion injury. J Invest Surg 10: 321-338.
38. Marathe GK, Davies SS, Harrison KA, Silva AR, Murphy RC, Castro-Faria-Neto H et al. 1999. Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem 274: 28395-28404.
39. Martin GS, Mannino DM, Eaton S, Moss M 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554.
40. Martins MA, Castro Faria Neto HC, Bozza PT, e Silva PM, Lima MC, Cordeiro RS et al. 1993. Role of PAF in the allergic pleurisy caused by ovalbumin in actively sensitized rats. J Leukoc Biol 53: 104-111.
41. Martins MA, Martins PM, Castro Faria Neto HC, Bozza PT, Dias PM, Cordeiro RS et al. 1988. Intravenous injections of PAF-acether induce platelet aggregation in rats. Eur J Pharmacol 149: 89-96.
42. Martins MA, Silva PM, Castro Faria Neto HC, Lima MC, Cordeiro RS et al. 1987. Interactions between local inflammatory and systemic haematological effects of PAF-acether in the rat. Eur J Pharmacol 136: 353-360.
43. Martins MA, Silva PM, Castro Faria Neto HC, Bozza PT, Dias PM, Lima MC et al. 1989. Pharmacological modulation of Paf-induced rat pleurisy and its role in inflammation by zymosan. Br J Pharmacol 96: 363-371.
44. Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Rabinovici R 1997. Platelet-activating factor (PAF) in experimental and clinical sepsis. Shock 7: 391-404.
45. McIntyre TM, Zimmerman GA, Prescott SM 1999. Biologically active oxidized phospholipids. J Biol Chem 274: 25189-25192.
46. Min JH, Wilder C, Aoki J, Arai H, Inoue K, Paul L et al. 2001. Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme. Biochemistry 40: 4539-4549.
47. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C 2004. Should we continue to target the platelet-activating factor pathway in septic patients? Crit Care Med 32: 585-588.
48. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S et al. 1988. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 82: 1983-1991.
49. Morgan EN, Boyle EM, Jr., Yun W, Kovacich JC, Canty Jr TG, Chi E et al. 1999. Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 100: II365-368.
50. Nagase T, Ishii S, Katayama H, Fukuchi Y, Ouchi Y, Shimizu T 1997. Airway responsiveness in transgenic mice overexpressing platelet-activating factor receptor. Roles of thromboxanes and leukotrienes. Am J Respir Crit Care Med 156: 1621-1627.
51. Nakajima K, Murakami M, Yanoshita R, Samejima Y, Karasawa K, Setaka M et al. 1997. Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating factor. J Biol Chem 272: 19708-19713.
52. Narahara H, Nishioka Y, Johnston JM 1993. Secretion of platelet-activating factor acetylhydrolase by human decidual macrophages. J Clin Endocrinol Metab 77: 1258-1262.
53. Narahara H, Kawano Y, Nasu K, Yoshimatsu J, Johnston JM, Miyakawa I 2003. Platelet-activating factor inhibits the secretion of platelet-activating factor acetylhydrolase by human decidual macrophages. J Clin Endocrinol Metab 88: 6029-6033.
54. Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S et al. 2004. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 32: 332-341.
55. Pinckard RN, Farr RS, Hanahan DJ 1979. Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J Immunol 123: 1847-1857.
56. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM 2000. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 69: 419-445.
57. Pritchard PH 1987. The degradation of platelet-activating factor by high-density lipoprotein in rat plasma. Effect of ethynyloestradiol administration. Biochem J 246: 791-794.
58. Rabinovici R, Yue TL, Farhat M, Smith 3rd EF, Esser KM, Slivjak M et al. 1990. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist. J Pharmacol Exp Ther 255: 256-263.
59. Riedemann NC, Guo RF, Ward PA 2003. The enigma of sepsis. J Clin Invest 112: 460-467.
60. Satoh N, Asano K, Naoki K, Fukunaga K, Iwata M, Kanazawa M et al. 1999. Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma. Am J Respir Crit Care Med 159: 974-979.
61. Schuster DP, Metzler M, Opal S, Lowry S, Balk R, Abraham E et al. 2003. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 31: 1612-1619.
62. Silva PM, Martins MA, Cordeiro RS, Vargaftig BB 1989. Late eosinophil mobilization induced by PAF-acether in the pleural cavity of rats. Braz J Med Biol Res 22: 1281-1285.
63. Snyder F, Lee TC, Blank M, Malone B, Woodard D, Robinson M 1985. Platelet-activating factor: alternate pathways of biosynthesis, mechanism of inactivation, and reacylation of lyso-PAF with arachidonate. Adv Prostaglandin Thromboxane Leukot Res 15: 693-696.
64. Stafforini DM 2001. PAF acetylhydrolase gene polymorphisms and asthma severity. Pharmacogenomics 2: 163-175.
65. Stafforini DM, Prescott SM, McIntyre TM 1987. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem 262: 4223-4230.
66. Stafforini DM, McIntyre TM, Carter ME, Prescott SM 1987. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 262: 4215-4222.
67. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM 1997. Platelet-activating factor acetylhydrolases. J Biol Chem 272: 17895-17898.
68. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM 2003. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 40: 643-672.
69. Stafforini DM, Numao T, Tsodikov A, Vaitkus D, Fukuda T, Watanabe N, et al. 1999. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest 103: 989-997.
70. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H et al. 1996. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 97: 2784-2791.
71. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM 1991. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 266: 11095-11103.
72. Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, Permpikul C et al. 2000. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother 44: 693-696.
73. Tetta C, Mariano F, Buades J, Ronco C, Wratten ML, Camussi G 1997. Relevance of platelet-activating factor in inflammation and sepsis: mechanisms and kinetics of removal in extracorporeal treatments. Am J Kidney Dis 30: S57-65.
74. Tjoelker LW, Eberhardt C, Unger J, Trong HL, Zimmerman GA, McIntyre TM et al. 1995. Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J Biol Chem 270: 25481-25487.
75. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B et al. 1995. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374: 549-553.
76. Unno N, Nakamura T, Kaneko H, Uchiyama T, Yamamoto N, Sugatani J et al. 2000. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan. J Vasc Surg 32: 263-267.
77. Van Amersfoort ES, Van Berkel TJ, Kuiper J 2003. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16: 379-414.
78. Wu X, Zimmerman GA, Prescott SM, Stafforini DM 2004. The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide. J Biol Chem 279: 36158-36165.
79. Yamada Y, Yokota M 1997. Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281 ->Arg mutation. Biochem Biophys Res Commun 236: 772-775.
80. Yamada Y, Ichihara S, Fujimura T, Yokota M 1998. Identification of the G994-> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 47: 177-181.
81. Yamada Y, Stafforini DM, Imaizumi T, Zimmerman GA, McIntyre TM, Prescott SM 1994. Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes. Proc Natl Acad Sci USA 91: 10320-10324.
82. Yoshida H, Imaizumi T, Fujimoto K, Itaya H, Hiramoto M, Yoshimizu N et al. 1998. A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension. Thromb Haemost 80: 372-375.
83. Yoshida H, Satoh K, Koyama M, Hiramoto M, Takamatsu S 1996. Deficiency of plasma platelet-activating factor acetylhydrolase: roles of blood cells. Am J Hematol 53: 158-164.
84. Zimmerman GA, McIntyre TM 2004. PAF, ceramide and pulmonary edema: alveolar flooding and a flood of questions. Trends Mol Med 10: 245-248.
85. Zimmerman GA, McIntyre TM, Prescott SM 1985. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J Clin Invest 76: 2235-2246.
86. Zimmerman GA, Elstad MR, Lorant DE, McLntyre TM, Prescott SM, Topham MK et al. 1996. Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions. Adv Exp Med Biol 416: 297-304.
87. Zimmerman GA, McIntyre TM, Mehra M, Prescott SM 1990. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol 110: 529-540.
88. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM 2002. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 30: S294-301.